LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Elenco Azioni・MacroGenics Inc

MacroGenics Inc

Chiusa

SettoreSettore sanitario

3.89 -8.69

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.86

Massimo

4.04

Metriche Chiave
By Trading Economics
Entrata	-23M -37M
Vendite	-20M 21M
EPS	-0.58
Margine di Profitto	-177.011
Dipendenti	293
EBITDA	-17M -32M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+48.94% upside

Dividendi
By Dow Jones
Utili prossimi	12 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	76M 263M
Apertura precedente	12.58
Chiusura precedente	3.89

Notizie sul Sentiment di mercato

By Acuity

100%

320 / 344 Classifica in Healthcare

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 giu 2026, 19:20 UTC

I principali Market Mover

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 giu 2026, 21:27 UTC

Utili

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 giu 2026, 20:19 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Hog Futures Tumble to Close Week -- Market Talk

5 giu 2026, 19:10 UTC

Discorsi di Mercato

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 giu 2026, 19:03 UTC

Discorsi di Mercato

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 giu 2026, 18:59 UTC

Discorsi di Mercato

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 giu 2026, 18:47 UTC

Discorsi di Mercato

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 giu 2026, 18:34 UTC

Discorsi di Mercato

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 giu 2026, 18:33 UTC

Acquisizioni, Fusioni, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 giu 2026, 17:50 UTC

Utili

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 giu 2026, 17:27 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 giu 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

5 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 15:26 UTC

Discorsi di Mercato

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 giu 2026, 15:25 UTC

Utili

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 giu 2026, 15:16 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 giu 2026, 15:16 UTC

Discorsi di Mercato

Zcash Tumbles After Exploit Found -- Market Talk

5 giu 2026, 15:09 UTC

Discorsi di Mercato

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 giu 2026, 15:07 UTC

Discorsi di Mercato

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 giu 2026, 15:05 UTC

Discorsi di Mercato

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

48.94% in crescita

Previsioni per 12 mesi

Media 6.33 USD 48.94%

Alto 9 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a MacroGenics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

320 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.